Microdosing induction is a novel method of starting buprenorphine/naloxone without patients
experiencing the opioid withdrawal that is a part of traditional induction. Patients take
small doses of buprenorphine/naloxone that increase slowly over a week. Although microdosing
induction has been supported anecdotally, its effectiveness is not known. The proposed study
will compare the effectiveness and safety of two induction strategies for transitioning
patients from opioids to buprenorphine/naloxone. All inductions will occur in an outpatient
telehealth opioid use disorder (OUD) treatment setting. The study will compare patients who
receive traditional induction versus microdosing induction. Primary outcomes include
effectiveness and safety. Secondary outcomes include treatment retention, self-reported use
of opioids during induction, return to opioid use, opioid appearance in drug screens,
craving/withdrawal symptoms, and patient satisfaction.
Phase:
Phase 4
Details
Lead Sponsor:
Bicycle Health
Treatments:
Buprenorphine Buprenorphine, Naloxone Drug Combination Naloxone